| Biomarker ID | 1843 |
| PMID | 30890858 |
| Year | 2019 |
| Biomarker | FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3); |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Tumor Stage T2 Vs T2a |
| Type of Biomarker | Prognostic |
| Cohort | 14 patients had tumor stage T1c, 10 had T2, 23 had T2a, 11 had T2b, 30 had T2c, 2 had T3, 6 had T3a, 8 had T3b, 1 had T4. Dataset: Long et. all |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.97 |
| Accuracy | 93.9% |
| Level Of Significance | p<0.05 |
| Method Used | RNA-Seq |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |